Mometasone/formoterol (MF/F) vs placebo
Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
- Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes onlyOR 0.71 [0.41, 1.23]894 participantsLow